首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

2055246

肺炎鏈球菌疫苗市場：依疫苗類型、目標族群、給藥途徑、通路和地區分類。

Pneumococcal Vaccines Market, By Vaccine Type, By Target Population, By Route of Administration, By Distribution Channel, By Geography

出版日期: 2026年04月01日 | 出版商:

Coherent Market Insights | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到2026年，肺炎鏈球菌疫苗市場規模將達到98.8億美元，到2033年將達到141.8億美元。預計從2026年到2033年，其複合年成長率將達到5.3%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	98.8億美元
歷史數據時期：	2020-2024	預測期：	2026-2033
2026年至2033年預測期間的複合年成長率：	5.30%	2033年市場規模預測：	141.8億美元

全球肺炎球菌疫苗市場成長的主要促進因素包括全球肺炎鏈球菌感染發生率的上升以及各國政府擴大免疫接種計劃。此外，大眾對肺炎球菌疫苗接種意識的提高也可能促進市場成長。然而，肺炎鏈球菌疫苗研發和生產的高成本可能會阻礙市場成長。持續進行研發工作，開發價格合理且有效的疫苗，預計在不久的將來創造新的機會。

市場動態

全球肺炎鏈球菌疫苗市場成長的主要驅動力是肺炎、腦膜炎和其他由肺炎鏈球菌引起的嚴重感染疾病在全球範圍內的日益普及。世界衛生組織（世衛組織）指出，肺炎是五歲以下兒童死亡的五大原因之一。此外，政府加大投入並透過國家免疫計劃推廣免疫接種項目，可望促進市場成長。然而，肺炎鏈球菌疫苗高昂的研發和生產成本可能會阻礙市場擴張。正在進行的評估新型多價肺炎鏈球菌疫苗製劑安全性和有效性的臨床試驗有望刺激市場成長。在新興經濟體，醫療基礎設施的建設為市場相關人員帶來了巨大的機會。

本研究的關鍵特徵

本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數對全球肺炎球菌疫苗市場的主要參與者進行了分析：公司亮點、產品系列、主要特點、財務表現和策略。
透過利用本報告中的見解，企業行銷負責人和經營團隊可以就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份「全球肺炎球菌疫苗市場報告」旨在為行業內的各種相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第9章競爭情勢

Pfizer Inc.
Merck & Co., Inc.
GlaxoSmithKline plc（GSK）
Sanofi
CSL Limited
Serum Institute of India Pvt. Ltd.
Vaxcyte, Inc.
Astellas Pharma Inc.
Panacea BIoTec Ltd.
Walvax BIoTechnology Co., Ltd.
Beijing Minhai BIoTechnology Co., Ltd.
Merck KGaA
Takeda Pharmaceutical Company Limited
AbbVie Inc.
Novartis AG
Johnson & Johnson
Biovac
Bharat BIoTech
Inovio Pharmaceuticals, Inc.
Hilleman Laboratories Pvt. Ltd.

第10章分析師建議

機會分析
分析師意見
一致的機會地圖

第11章參考文獻與調查方法

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI2295

Pneumococcal Vaccines Market is estimated to be valued at USD 9.88 Bn in 2026 and is expected to reach USD 14.18 Bn by 2033, growing at a compound annual growth rate (CAGR) of 5.3% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 9.88 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	5.30%	2033 Value Projection:	USD 14.18 Bn

Global pneumococcal vaccines market growth is driven by factors such as rising incidence of pneumococcal diseases worldwide and growing immunization programs by various governments. Moreover, increasing awareness among people regarding pneumococcal vaccination can also drive the market growth. However, high costs associated with pneumococcal vaccines development and production can hamper the market growth. Ongoing research activities for developing affordable and effective vaccines can offer new opportunities in the near future.

Market Dynamics

Global pneumococcal vaccines market growth is primarily driven by rising prevalence of pneumococcal pneumonia, meningitis, and other serious infections caused by Streptococcus pneumoniae bacteria worldwide. As per the World Health Organization (WHO), pneumonia is one of the top five causes of death in children under age of 5 years. Moreover, increasing government funding and initiatives to promote immunization programs through national immunization schedules can drive the market growth. However, high research, development and production costs of pneumococcal vaccines can hamper the market expansion. Ongoing clinical trials assessing the safety and efficacy of new multivalent pneumococcal formulations can drive the market growth. Emerging economies present significant opportunities for market players owing to improving healthcare infrastructures in these countries.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global pneumococcal vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Pfizer Inc., Merck & Co., GSK plc., and Sanofi.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global pneumococcal vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.

Market Segmentation

By Vaccine Type (Revenue, USD Bn, 2021 - 2033)
Pneumococcal Conjugate Vaccines (PCVs)
- PCV13 (Prevnar 13/Prevenar 13)
- PCV10 (Synflorix)
- PCV7 (Prevnar/Prevenar)
Pneumococcal Polysaccharide Vaccines (PPVs)
- PPSV23 (Pneumovax 23)
- PPSV14 (Pneumo 14)
By (Revenue, USD Bn, 2021 - 2033) Target Population
Adults (a‰¥ 65 years)
Children (< 5 years)
High-Risk Adults (18-64 years)
By Route of Administration (Revenue, USD Bn, 2021 - 2033)
Intramuscular
Subcutaneous
By (Revenue, USD Bn, 2021 - 2033) Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
Pfizer Inc.
Merck & Co., Inc.
GlaxoSmithKline plc (GSK)
Sanofi
CSL Limited
Serum Institute of India Pvt. Ltd.
Vaxcyte, Inc.
Astellas Pharma Inc.
Panacea Biotec Ltd.
Walvax Biotechnology Co., Ltd.
Beijing Minhai Biotechnology Co., Ltd.
Merck KGaA
Takeda Pharmaceutical Company Limited
AbbVie Inc.
Novartis AG
Johnson & Johnson
Biovac
Bharat Biotech
Inovio Pharmaceuticals, Inc.
Hilleman Laboratories Pvt. Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Pneumococcal Vaccines Market, By Vaccine Type
- Global Pneumococcal Vaccines Market, By Target Population
- Global Pneumococcal Vaccines Market, By Route of Administration
- Global Pneumococcal Vaccines Market, By Distribution Channel
- Global Pneumococcal Vaccines Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Pneumococcal Vaccines Market, By Vaccine Type, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Pneumococcal Conjugate Vaccines (PCVs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  - PCV13 (Prevnar 13/Prevenar 13)
  - PCV10 (Synflorix)
  - PCV7 (Prevnar/Prevenar)
Pneumococcal Polysaccharide Vaccines (PPVs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  - PPSV23 (Pneumovax 23)
  - PPSV14 (Pneumo 14)

5. Global Pneumococcal Vaccines Market, By Target Population, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Adults (≥ 65 years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Children (< 5 years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
High-Risk Adults (18-64 years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

6. Global Pneumococcal Vaccines Market, By Route of Administration, 2021 - 2033, (USD Bn)

Intramuscular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Global Pneumococcal Vaccines Market, By Distribution Channel, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

8. Global Pneumococcal Vaccines Market, By Region, 2021 - 2033, (USD Bn)

Introduction
- Market Share (%) Analysis, 2026,2028 & 2033, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2033, (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Vaccine Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Target Population, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Vaccine Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Target Population, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Vaccine Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Target Population, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Vaccine Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Target Population, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Vaccine Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Target Population, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Vaccine Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Target Population, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country/Sub-region, 2021 - 2033, (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive Landscape

Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline plc (GSK)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
CSL Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Serum Institute of India Pvt. Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Vaxcyte, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Panacea Biotec Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Walvax Biotechnology Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Beijing Minhai Biotechnology Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck KGaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Biovac
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bharat Biotech
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Inovio Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Hilleman Laboratories Pvt. Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies